Active vs. Non-Active Multiple Sclerosis: Key Distinctions
Active disease in MS is defined by the presence of clinical relapses and/or MRI evidence of new inflammatory activity (gadolinium-enhancing lesions or new/enlarging T2 lesions), while non-active (stable) disease shows no relapses and no new MRI lesions over a defined surveillance period. 1
Core Definitions
Active Disease is characterized by:
- Clinical activity: One or more relapses within the past 12 months
- MRI activity: Gadolinium-enhancing lesions (indicating blood-brain barrier breakdown) OR new/enlarging T2 lesions on surveillance imaging
- Either criterion alone is sufficient to classify disease as active 1
Non-Active (Stable) Disease requires:
- No clinical relapses in the previous year
- No new lesions on MRI (no gadolinium enhancement and no new T2 lesions)
- Both criteria must be met simultaneously 1, 2
Why This Distinction Matters Clinically
MRI detects disease activity 5-10 times more frequently than clinical relapses, meaning most inflammatory lesions are clinically silent 1. This makes the active/non-active distinction heavily dependent on imaging surveillance rather than symptoms alone.
In real-world practice, MRI identifies 59.1% of active cases independently, while relapses alone identify only 12.7%, and both together account for 28.3% 2. This underscores why patients classified as "non-active" based on clinical assessment alone may actually have ongoing disease activity.
Critical Pitfall in Non-Active Classification
A major concern: In the EXPAND trial, 53% of patients classified as "non-active" at baseline actually demonstrated disease activity during follow-up, with 74.1% of this activity detected by MRI, only 8.4% by relapse, and 17.5% by both 2. This reveals that "non-active" is a snapshot classification that doesn't guarantee continued stability.
Surveillance Implications
For stable patients on established disease-modifying therapy:
- Routine follow-up brain MRI is recommended yearly 1
- Gadolinium contrast is NOT routinely required for surveillance in stable patients unless showing disease activity is needed to change treatment 1
- New or enlarging T2 lesions alone indicate inflammatory activity even without gadolinium enhancement 1
For patients with active disease:
- Gadolinium-enhanced MRI is recommended to detect active inflammation and guide treatment escalation 1
- Contrast is particularly valuable when treatment decisions depend on demonstrating active lesions 1
The Real-World Gap
In clinical practice, only 58.7% of non-active patients received an MRI in the past year compared to 87.7% of active patients 2. This is problematic because most disease activity is detected via MRI, meaning non-active patients may be under-monitored and miss opportunities for treatment adjustment before disability accumulates.
The key takeaway: "Non-active" disease requires both clinical AND radiological stability, but this classification is time-dependent and requires regular MRI surveillance to maintain accuracy, as subclinical activity is common and prognostically important.